Anti-obesity Potential Of Isolated Demethoxycurcumin Against High Fat Diet Induced Obesity In Albino Wistar Rats | 14846
Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
As obesity has become a major lifestyle health problem in the world, the present study was designed to investigate the possible
anti-obesity and hypolipidemic effect of demethoxycurcumin (DMC), a bioactive phenolic component of turmeric spice, for
the first time, using
anti-obesity models and to explore the linking mechanism behind it by evaluating bodyweight, food
intake, lipid profiles, renal, hepatic, cardiac function markers, lipid peroxidation, and the glucose and insulin levels in blood and
liver tissue in rats.
Rats (80-100 gms) were divided into 4 groups with n=6. Group 1 served as control and was fed with normal diet. All other
animals were treated with high fat died for 14 continuous weeks which was followed by its equal distribution in three equal
groups. Group 2 received HFD with no supplement; Group 3 received DMC (20 mg/kg) + HFD. DMC was started administered
week from the start time for the treatment. Group 3 received DMC (40 mg/kg) + HFD.
Body weight, lipid profile & renal function (urea, uric acid creatinine) ALT & AST activities, cardiac markers, (LDH, C.K-
NAC and MB) the oxidative stress marker reduced glutathione (GSH), and malondialdehyde (MDA) catalase activity, in addition
to glucose, insulin, and insulin resistance in serum & tissues were analysed.
Results revealed that HFD significantly increased final body weight, triglycerides (TG), total cholesterol, & LDL concentration
compared with controls. DMC treatment significantly improved obesity and its associated metabolic problems in different degrees
in experimental animals proving its distinct anti-obesity effect.
Sumeet Gullaiya has completed his Ph.D. (Pharmacology) at the age of 29 years from Delhi Institute of Pharmaceutical Sciences and Research,
University of Delhi, India. He is working as assistant Professor in Amity University, a premier research oriented academic organization. He has
published more than 15 papers in reputed journals of national and international repute. He is also serving as an editorial board member and reviewer
for reputed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals